04-29 Alliance Pharma Limited Appoints Jonathan Mark Leese as Director, Effective April 30, 2026 CI
25-05-15 Alliance Pharma Delists from London Bourse's AIM After Acquisition MT
25-05-14 Aegros Bidco Completes Takeover of Alliance Pharma MT
25-05-14 Alliance Pharma Says Aegros Bidco Recommends Acquisition Of Alliance Pharma RE
25-05-13 Alliance Pharma plc Announces the Termination of Camillo Pane as Director, Effective May 14, 2025 CI
25-05-13 Alliance Pharma plc Announces the Termination of Mr. Richard Alexander Mckenzie as Director, Effective from May 14, 2025 CI
25-05-13 Alliance Pharma Plc Announces the Termination of Martin Sutherland as Director, Effective May 14, 2025 CI
25-05-13 Alliance Pharma plc Announces the Termination of Kristof Leon Neirynck as Director, Effective from May 14, 2025 CI
25-05-13 Alliance Pharma plc Announces the Termination of Richard Crispin Jones as Director, Effective from May 14, 2025 CI
25-05-13 Alliance Pharma Plc Announces the Termination of Eva-Lotta Saga Sjostedt as Director, Effective May 14, 2025 CI
25-05-13 An undisclosed funds, managed by DBAY Advisors Limited, An undisclosed funds, managed by Baring Asset Management Limited, Edmond De Rothschild Equity Strategies IV Fund, a fund managed by Edmond de Rothschild Private Equity Management Ltd. and an undisclosed buyer completed the acquisition of remaining 71.9% stake in Alliance Pharma plc from Andrew Franklin, Richard Jones, Nick Sedgwick, Slater Investments Limited and others. CI
25-05-13 Aegros' Takeover of Alliance Pharma Sanctioned by Court MT
25-04-29 Slater Investments Discloses 4.37% Stake In Alliance Pharma As Of 25-Apr-2025 RE
Manager TitleAgeSince
Chief Executive Officer 54 2024-05-12
Director of Finance/CFO 60 2015-09-27
Chief Tech/Sci/R&D Officer - 2024-12-31
Director TitleAgeSince
Director/Board Member 60 2015-09-27
Director/Board Member 48 2021-11-30
Director/Board Member 57 2023-01-31
Date Insider Type Main position Quantity % Market Cap. Importance
6/27/24 Free

Chief Executive Officer

906,862 0.1678%
10/16/23 Exercice

Chief Executive Officer

98,342 0.0182%
10/16/23 Exercice

Chief Financial Officer

55,592 0.0103%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+0.15% - - 480M
+6.63%+5.13%+68.86%+145.20% 1,224B
+1.53%+2.84%+47.48%+89.01% 662B
+1.68%+1.96%+29.16%+109.31% 514B
+0.73%+2.45%+54.26%+68.96% 388B
+3.83%-0.62%+69.01%+42.32% 361B
+2.38%+2.65%+34.31%+57.95% 302B
+2.26%+0.55%+3.92%+28.92% 271B
+1.97%+3.01%+57.91%+76.14% 249B
+4.03%+5.36%+39.76%+116.14% 205B
Average +2.11%+2.59%+44.96%+81.55% 464.09B
Weighted average by Cap. +2.26%+3.04%+50.45%+96.49%
Logo Alliance Pharma plc
Alliance Pharma plc is a United Kingdom-based international consumer healthcare company. The principal activity of the Company is to act as a holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. Its segments include Consumer Healthcare brands and Prescription Medicines. Its Consumer Healthcare brands include the Kelo-Cote franchise, Amberen, Nizoral, MacuShield, Aloclair, Vamousse, and other consumer healthcare brands. Its Prescription Medicines include Hydromol, Flamma Franchise, Forceval and other prescription medicines. Its products include Aloclair Plus Gel, Aloclair Plus Spray, Aloclair Plus Mouthwash, Anbesol Adult Strength Gel, Anbesol Teething Gel, Anbesol Liquid, Atopiclair Cream, and Atopiclair Lotion. It holds marketing rights to around 80 consumer healthcare brands and prescription medicines, which are sold worldwide in more than 100 countries.
Employees
290
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Alliance Pharma plc